Results 171 to 180 of about 6,317 (201)

Integrated Safety and Efficacy Among Patients Receiving Benralizumab for Up to 5 Years

Journal of Allergy and Clinical Immunology: in Practice, 2021
Arnaud Bourdin
exaly  

Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies

Lancet Respiratory Medicine,the, 2020
Gerard J Criner, Bartolome R Celli, Dave Singh   +2 more
exaly  

Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthma

Allergy: European Journal of Allergy and Clinical Immunology, 2020
Ioana Agache, Claudio A Rocha, Margarita Posso   +2 more
exaly  

Benralizumab effect on severe chronic rhinosinusitis with nasal polyps (CRSwNP): A randomized double‐blind placebo‐controlled trial

Clinical and Experimental Allergy, 2021
Jody Tversky, Andrew P Lane, Antoine E Azar   +2 more
exaly  

Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial

Lancet Respiratory Medicine,the, 2019
Eugene R Bleecker, J Mark Fitzgerald, Ubaldo J Martin   +2 more
exaly  

Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies

Lancet Respiratory Medicine,the, 2018
J Mark Fitzgerald, Eugene R Bleecker, Andrew Menzies-Gow   +2 more
exaly  

Benralizumab/omalizumab

Reactions Weekly, 2022
openaire   +2 more sources

Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study

Lancet Respiratory Medicine,the, 2014
Christopher E Brightling, Reynold A Panettieri, Mona Bafadhel   +2 more
exaly  

Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma

New England Journal of Medicine, 2017
Parameswaran Nair, Sally E Wenzel, Klaus F Rabe   +2 more
exaly  

Aminophylline/benralizumab

Reactions Weekly, 2023
openaire   +1 more source